Letters to the Editor representative survey, 5 we investigated the long-term impact of ADHD medications on adult height in naturalistic conditions. In a recent study using data from the NESARC, Bernardi et al 6 identified 807 subjects with a DSM-IV diagnosis of ADHD among whom 27.6% reported having received specific medication for ADHD. We compared adult height between 3 mutually independent groups: (1) participants with a lifetime DSM-IV diagnosis of ADHD who received medication, (2) participants with a lifetime DSM-IV diagnosis of ADHD who never received medication, and (3) participants without such a condition. Multinomial logistic regressions were performed following adjustments for confounders known to affect height, ie, sex, age, and ethnicity. Analyses were also performed stratified by gender. Because of the weighting and clustering used in the NESARC design, all statistical analyses were performed using the Taylor series linearization method, a designed-based method implemented using Table  1) . Similar results were obtained when comparisons were stratified by sex. Also, no significant association between treatment duration and adult height was observed (total sample: Wald F 7,65 = 0.04, P = .834; female: Wald F 6,65 = 0.21, P = .652; male: Wald F 6,65 = 0.08, P = .781).
The strengths of this study lie in the naturalistic conditions and the large and nationally representative sample. Based on pharmacoepidemiologic studies, 7, 8 we can reasonably consider that most of the participants who received specific medication for ADHD were treated with methylphenidate. Data on dose reduction, treatment discontinuation (eg, weekend breaks and summer breaks), and treatment interruption were not available in this study and have been positively associated with growth velocity. 3, 9, 10 Such interventions are commonly prescribed in case of significant slowdown in growth of children treated with methylphenidate and must therefore be taken into consideration in the interpretation of our results.
As did Biederman et al, 4 we found no significant association between height into adulthood and either ADHD or medication Percentages and means are weighted values. b Wald F examining difference across groups was estimated using Wald F statistics with df = 1,65. c Wald F examining difference across groups was estimated using Wald F statistics with df = 4,65. d Wald F adjusted for sex, race/ethnicity, and age was estimated using Wald F statistics with df = 7,65. e Wald F adjusted for race/ethnicity and age was estimated using Wald F statistics with df = 6,65. Abbreviations: ADHD = attention-deficit/hyperactivity disorder, NESARC = National Epidemiologic Survey on Alcohol and Related Conditions.
